Skin capillary density in ovarian cancer; a potential biomarker of Bevacizumab treatment

被引：0
|
作者：
Cass, G. [1 ]
Newton, C. [2 ]
Pawade, J. [3 ]
Kanavou, S. [1 ]
机构：
[1] Univ Bristol, Bristol, Avon, England
[2] Univ Hosp, Bristol, Avon, England
[3] North Bristol Trust, Bristol, Avon, England
来源：
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY | 2021年 / 128卷
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
2359
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [1] SKIN CAPILLARY DENSITY AS A NOVEL BIOMARKER OF CYTOTOXIC AND BEVACIZUMAB TREATMENT IN OVARIAN CANCER: A PROSPECTIVE CLINICAL TRIAL
    Cass, G.
    Lewes, R.
    Pawade, J.
    Newton, C.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A209 - A210
  • [2] Utilizing a Pathomics Biomarker to Predict the Effectiveness of Bevacizumab in Ovarian Cancer Treatment
    Gilley, Patrik
    Zhang, Ke
    Abdoli, Neman
    Sadri, Youkabed
    Adhikari, Laura
    Fung, Kar-Ming
    Qiu, Yuchen
    [J]. BIOENGINEERING-BASEL, 2024, 11 (07):
  • [3] Bevacizumab in the treatment of ovarian cancer
    Han, Ernest S.
    Monk, Bradley J.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (10) : 1339 - 1345
  • [4] Bevacizumab in the Treatment of Ovarian Cancer
    Florian Heitz
    Philipp Harter
    Jana Barinoff
    Bianca Beutel
    Paevi Kannisto
    Jacek P. Grabowski
    Julia Heitz
    Christian Kurzeder
    Andreas du Bois
    [J]. Advances in Therapy, 2012, 29 : 723 - 735
  • [5] Bevacizumab in the treatment of ovarian cancer
    Eskander, Ramez N.
    Randall, Leslie M.
    [J]. BIOLOGICS-TARGETS & THERAPY, 2011, 5 : 1 - 5
  • [6] Bevacizumab in the Treatment of Ovarian Cancer
    Heitz, Florian
    Harter, Philipp
    Barinoff, Jana
    Beutel, Bianca
    Kannisto, Paevi
    Grabowski, Jacek P.
    Heitz, Julia
    Kurzeder, Christian
    du Bois, Andreas
    [J]. ADVANCES IN THERAPY, 2012, 29 (09) : 723 - 735
  • [7] Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?
    Ferrara, Napoleone
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (11)
  • [8] Cost-effectiveness of a predictive biomarker for bevacizumab responsiveness in the primary treatment of ovarian cancer
    Barnett, I.
    Alvarez-Secord, A.
    Cohn, D.
    Leath, C.
    Peterson, B.
    Myers, E.
    Havrilesky, L.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 125 : S66 - S66
  • [9] Reversibility of capillary density after discontinuation of bevacizumab treatment
    Steeghs, N.
    Rabelink, T. J.
    ' t Roodt, J. Op
    Batman, E.
    Cluitmans, F. H. M.
    Weijl, N. I.
    de Koning, E.
    Gelderblom, H.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (05) : 1100 - 1105
  • [10] The roles and limitations of bevacizumab in the treatment of ovarian cancer
    Hidekatsu Nakai
    Noriomi Matsumura
    [J]. International Journal of Clinical Oncology, 2022, 27 : 1120 - 1126
12345